Journey Medical (DERM) risk factors

59 risks, 4 new, 3 dropped, 10 reworded since the prior year. Journey Medical added new risk disclosures addressing import tariffs from India, FDA funding cuts, and changing presidential administration policies. The company faces ongoing generic competition threats and patent challenges for products like Qbrexza, Amzeeq, Zilxi, and Emrosi. Fortress maintains voting control through Class A common stock, potentially deterring control changes.

58 risks. Substantial doubt exists regarding the company's ability to continue as a going concern, requiring additional funding. Operations rely heavily on dermatology product sales, facing generic competition and lack of patent protection for key products. Dependence on third parties for manufacturing Emrosi creates significant supply and clinical trial risks.